Skip to content

Treatment outcomes in cytomegalovirus anterior uveitis

Treatment outcomes in cytomegalovirus anterior uveitis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20230401002
Enrollment
75
Registered
2023-04-01
Start date
2002-01-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cytomegalovirus anterior uveitis Cytomegalovirus anterior uveitis CMV Treatment outcomes Viral anterior uveitis

Interventions

Patients who were treated with systemic ganciclovir (Intravenous or oral),Patients who were treated with 2% Ganciclovir ED or Ganciclovir gel
Treatment,Treatment
Systemic ganciclovir,Topical ganciclovir

Sponsors

None listed

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with signs and symptoms which are compatible with cytomegalovirus anterior uveitis 2. Patients with aqueous PCR positive for cytomegalovirus 3. Patients who was treated with topical or systemic ganciclovir

Exclusion criteria

Exclusion criteria: 1. Patients who were diagnosed as CMV intermediate uveitis or CMV retinitits 2. Patients who were diagnosed as uveitis from other causes e.g. Infection, Autoimmune disease, Idiopathic 3. Patients with aqueous PCR positive for other organism or mixed organism 4. Patients who were treated with combination therapy 5. Immunocompromised patients 6. Patients with age under 18 7. In case of failure in first treatment protocol and other treatments were introduced. Data collection will select only first treatment protocol as failure of treatment

Design outcomes

Primary

MeasureTime frame
Response to treatment when response or failure to treatment was noted Percentage of response

Secondary

MeasureTime frame
Time to response duration from starting of treatment to the time when resolution of A/C cell is documented duration from starting of treatment to the time when resolution of A/C cell is documented,Time to recurrence When next episode of inflammation happened uration from starting of treatment to the time when next episode of inflammation happened,Visual acuity When respond or fail to treatment Visual acuity measurement by ETDRS chart,IOP When respond or fail to treatment Air puff tonometer and Application tonometry

Countries

Thailand

Contacts

Public ContactAssist. Prof. Sutasinee Boonsopon

Faculty of Medicine Siriraj Hospital Mahidol University

sutasinee.boo@mahidol.edu0943493842

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026